PTGX

Protagonist Therapeutics Inc.

Price

$154.94

return (12m)

175.45%

p/e

122.24

p/bv

12.04

DIVIDEND YIELD

0.00%

PTGX price

Protagonist Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PTGX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

13.30%

3 months

51.89%

1 year

175.45%

2 years

269.79%

5 years

214.79%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals PTGX

Valuation

P/E

122.24

Sector -4.38

Industry -4.38

P/BV

12.04

Sector 2.02

Industry 2.02

P/Revenue (PSR)

35.94

Sector -4.40

Industry -4.40

EV/EBITDA

58.76

Sector -263.09

Industry -263.09

EV/EBIT

58.91

Sector -702.90

Industry -702.90

P/EBITDA

169.26

Sector -4.39

Industry -4.39

P/EBIT

173.73

Sector -4.73

Industry -4.73

P/Total Assets

11.45

Sector 1.49

Industry 1.49

P/Net Current Assets

13.28

Sector -11.70

Industry -11.70

P/Working Capital

13.16

Sector -3.19

Industry -3.19

EPS

1.26

Sector -2.14

Industry -2.14

BVPS

12.75

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

74.56%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

74.38%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

20.69%

Sector -38.22%

Industry -38.22%

Net Profit Margins

29.40%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.24

Sector 0.03

Industry 0.03

Profitability

ROE

9.85%

Sector -65.14%

Industry -65.14%

ROA

9.36%

Sector -65.53%

Industry -65.53%

ROIC

559.06%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

21.71

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-4.92

Sector -6.07

Industry -6.07

Net Debt / EBIT

-4.93

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.93

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.95

Sector 0.41

Industry 0.41

Liabilities/Assets

0.05

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

59.44%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Protagonist Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$154.94

Fair Value

$19.01

Upside Return potential.

-87.73%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals PTGX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PTGX Protagonist Therapeutics Inc.	$154.94	175.64%	0.00%	122.24	12.04	9.85%	29.40%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PTGX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Protagonist Therapeutics

Protagonist Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

20 years

Founded: 2006

2016

Time since IPO - 10 years

79

Employees

Protagonist Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $10.14 billion, with shareholders equity totaling $841.54 million.

The company employs approximately 79 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Protagonist Therapeutics Inc. reported $281.99 million in revenue, generating net income of $82.91 million.

Key financial metrics include a P/E ratio of 122.24, a price-to-book (P/B) ratio of 12.04, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PTGX.

Market cap

$10.14 billion

Net worth

$841.54 million

$841,540,000.00

Assets

$885.54 million

$885,540,000.00

Total Shares Outstanding

66.00 million

66,000,000

Average Daily Trading Volume

$722.30 Thousand

$722,300.20

Sector

Health Care

Industry

Biotechnology

PTGX

PTGX revenue and profits

Financial Results PTGX

DRAG THE FRAME TO SEE MORE DATA

PTGX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Protagonist Therapeutics (PTGX) today?

A cotação de Protagonist Therapeutics (PTGX) hoje está em US$ 154.94, com uma variação de 175.45% em relação ao último ano. A cotação de Protagonist Therapeutics (PTGX) iniciou o ano negociando na casa dos US$ 87.34 e hoje está em US$ 154.94. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Protagonist Therapeutics (PTGX) e dados de ações do Ibovespa e mercados internacionais.

Quando Protagonist Therapeutics (PTGX) paga dividendos?

Protagonist Therapeutics (PTGX) não distribuiu dividendos no último ano.

Is Protagonist Therapeutics (PTGX) a good investment?

Atualmente, Protagonist Therapeutics (PTGX) está cotada a US$ 154.94, com um P/L de 122.24, representando um desvio de 1,329% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 175.45 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 175.45%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Protagonist Therapeutics (PTGX) stock?

Investir em ações de Protagonist Therapeutics (PTGX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Protagonist Therapeutics (PTGX) yield today?

A rentabilidade de Protagonist Therapeutics (PTGX) foi de 13.30% no último mês, 175.45% no último ano e 214.79% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Protagonist Therapeutics (PTGX) hoje, o investimento total seria de US$ 15,494.00, com base na cotação atual de US$ 154.94.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 42,678.22
Em 5 anos: US$ 48,773.56
Em 10 anos: US$ 15,494.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PTGX

Protagonist Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PTGX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING PTGX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Protagonist Therapeutics

Protagonist Therapeutics Inc.

United States

20 years

2016

79

PROFIT X PRICE PTGX

Financial Results PTGX

PTGX cash flow

Asset, Revenue and Profit Growth - PTGX

PTGX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions